Pharmacology of Proton Pump Inhibitors

Introduction/Overview

Proton pump inhibitors (PPIs) represent a cornerstone class of therapeutic agents in the management of acid-related disorders. Since the introduction of omeprazole in the late 1980s, these drugs have largely superseded histamine H₂-receptor antagonists as the most potent and reliable means of suppressing gastric acid secretion. Their development marked a significant advancement in gastroenterology, offering profound and sustained acid suppression that facilitates healing in conditions where acid plays a central pathogenic role. The clinical impact of PPIs is substantial, as they are among the most widely prescribed medications globally, reflecting the high prevalence of gastroesophageal reflux disease (GERD), peptic ulcer disease, and other hypersecretory states.

The fundamental importance of PPIs lies in their targeted mechanism. They act as irreversible inhibitors of the final common pathway of gastric acid secretion: the hydrogen/potassium adenosine triphosphatase (H⁺/K⁺ ATPase) enzyme, colloquially known as the proton pump. This enzyme resides in the secretory canaliculus of the gastric parietal cell and is responsible for the active transport of hydrogen ions into the gastric lumen. By covalently binding to and deactivating this pump, PPIs produce a profound and long-lasting antisecretory effect that is not dependent on the specific stimulus for acid secretion, be it gastrin, histamine, or acetylcholine.

Learning Objectives

• Describe the molecular mechanism of action of proton pump inhibitors, including their activation and irreversible binding to the H⁺/K⁺ ATPase enzyme.
• Explain the key pharmacokinetic properties of PPIs, particularly the implications of their short plasma half-life, acid-lability, and requirement for activation in an acidic environment.
• Identify the major approved clinical indications for PPI therapy and the rationale for their use in each condition.
• Analyze the spectrum of adverse effects associated with long-term PPI use, including potential risks such as nutrient deficiencies, infections, and bone fractures.
• Evaluate significant drug-drug interactions involving PPIs, with emphasis on interactions mediated by the cytochrome P450 system and altered gastric pH.

Classification

Proton pump inhibitors are classified as substituted benzimidazoles, sharing a common core chemical structure. This classification is based on their pharmacophore, which is essential for their mechanism of action. All PPIs are prodrugs that require activation in an acidic environment. They can be categorized by their chemical generation and metabolic pathways, though all members share the same fundamental target.

Chemical Classification and Members

The class comprises several agents, which are often grouped by their development timeline and metabolic characteristics.

• First-Generation PPIs: Omeprazole, lansoprazole, and pantoprazole are often considered first-generation. They exhibit greater potential for cytochrome P450-mediated drug interactions.
• Second-Generation PPIs: Rabeprazole, esomeprazole (the S-isomer of omeprazole), and dexlansoprazole (the R-enantiomer of lansoprazole) are frequently described as second-generation. These agents may offer more consistent pharmacokinetics, less inter-individual variability, and, in some cases, a reduced propensity for certain drug interactions.

It is critical to note that all PPIs are prodrugs. In their administered form, they are weak bases and exist as neutral, lipophilic compounds. This property allows them to diffuse across cell membranes into the parietal cell. They are chemically unstable in acidic media, which necessitates their formulation as enteric-coated granules or tablets to prevent degradation in the stomach prior to absorption.

Mechanism of Action

The pharmacodynamic action of proton pump inhibitors is characterized by a highly specific and irreversible inhibition of gastric acid secretion. This effect is achieved through a multi-step process that capitalizes on the unique physiology of the gastric parietal cell.

Molecular and Cellular Mechanism

The target of all PPIs is the H⁺/K⁺ ATPase, an enzyme integral to the gastric parietal cell’s secretory membrane. This pump functions as an electroneutral exchanger, utilizing the energy from ATP hydrolysis to transport H⁺ ions out of the cell and K⁺ ions into the cell against steep concentration gradients. The mechanism of PPI action involves several sequential stages:

1. Absorption and Systemic Circulation: The administered PPI prodrug is absorbed in the small intestine and enters the systemic circulation.
2. Diffusion into Parietal Cells: As weak bases (pK_a ≈ 4.0), the neutral PPIs readily diffuse across the lipid bilayer of the parietal cell from the bloodstream into the cytoplasm.
3. Trapping and Accumulation: Within the parietal cell cytoplasm, the PPI encounters the acidic environment of the secretory canaliculus—the site of active acid secretion. The canalicular pH is less than 2.0. The PPI, being a weak base, becomes protonated in this low-pH compartment. Protonation converts the drug into a charged, sulfenamide species that cannot diffuse back across the membrane, leading to its selective accumulation within the acid-producing compartment of the active parietal cell. This process is known as “acid trapping.”
4. Activation and Covalent Binding: The protonated sulfenamide form is the chemically active species. It reacts covalently with cysteine residues on the extracellular (luminal) domain of the H⁺/K⁺ ATPase enzyme. The binding is via disulfide bonds, primarily with cysteine 813 in humans (cysteine 822 in the pig enzyme model), though other cysteines may also be involved depending on the specific PPI. This covalent modification irreversibly inactivates the pump.
5. Inhibition of Acid Secretion: The inactivated pump can no longer transport protons. Since the binding is irreversible, acid secretion remains suppressed until new pump molecules are synthesized and incorporated into the canalicular membrane. The synthesis of new pumps has a half-life of approximately 24 to 48 hours, which explains the prolonged duration of action despite the short plasma half-life of the drugs.

The requirement for activation in an acidic environment means that PPIs preferentially inhibit actively secreting pumps. Pumps that are dormant in the tubulovesicles within the cytoplasm are not exposed to the acidic environment and thus are not inhibited. This characteristic has important dosing implications, as maximal effect is achieved when the drug is administered before a meal, which stimulates pump activation and translocation to the secretory membrane.

Pharmacokinetics

The pharmacokinetic profiles of proton pump inhibitors are defined by their acid-lability, their status as prodrugs, and significant first-pass metabolism. Understanding these properties is essential for optimizing their clinical use.

Absorption

Absorption of PPIs occurs primarily in the small intestine. Due to their rapid degradation in gastric acid, all oral formulations are designed to protect the drug from stomach acid. This is achieved through enteric-coated granules (often contained within a capsule or tablet) or, in the case of some formulations, through the use of a bicarbonate buffer. The bioavailability of PPIs is incomplete and variable, ranging from approximately 30% to over 80%, largely due to significant first-pass metabolism. Food can affect absorption; co-administration with food, particularly a high-fat meal, may delay the absorption of some PPIs by delaying gastric emptying and the release of enteric-coated granules. Standard clinical guidance is to administer PPIs 30 to 60 minutes before the first major meal of the day to synchronize peak plasma levels with maximal activation of proton pumps.

Distribution

PPIs are extensively bound to plasma proteins, primarily albumin, with protein binding exceeding 95%. Their volume of distribution is relatively low, typically around 0.1 to 0.4 L/kg, consistent with distribution largely within the extracellular fluid. As weak bases, they concentrate in acidic compartments, most notably the acidic canaliculus of the parietal cell, as described in the mechanism of action.

Metabolism

Metabolism is the primary route of elimination for all PPIs. They undergo extensive hepatic metabolism via the cytochrome P450 (CYP) system. The principal isoenzymes involved are CYP2C19 and CYP3A4, though the relative contribution of each varies between agents.

• CYP2C19 Polymorphism: This polymorphism has a clinically significant impact on PPI pharmacokinetics. Individuals can be classified as extensive metabolizers (EM), intermediate metabolizers (IM), poor metabolizers (PM), or ultra-rapid metabolizers (UM). Poor metabolizers, who lack functional CYP2C19, exhibit significantly higher PPI plasma concentrations (AUC) and longer elimination half-lives compared to extensive metabolizers. This can lead to more profound and sustained acid suppression. Conversely, ultra-rapid metabolizers may have subtherapeutic drug levels. The clinical relevance of this polymorphism is most pronounced for omeprazole and lansoprazole, while rabeprazole and pantoprazole have alternative metabolic pathways that may lessen the impact.
• Specific Metabolic Pathways: Omeprazole and lansoprazole are predominantly metabolized by CYP2C19. Pantoprazole is metabolized mainly by CYP2C19 but also via a non-enzymatic, cytosolic sulfotransferase pathway. Rabeprazole undergoes non-enzymatic reduction to a thioether metabolite, with minor CYP involvement (primarily CYP3A4), making it less susceptible to CYP2C19 polymorphism. Esomeprazole metabolism is also dependent on CYP2C19, but its stereoselective clearance results in less variability than the racemic omeprazole.

Excretion

The metabolites of PPIs are primarily excreted in the urine, with a smaller fraction eliminated in the feces. Very little, if any, unchanged drug is found in the urine. The elimination half-life (t_1/2) in plasma is short, usually between 1 and 2 hours. However, the pharmacodynamic effect on acid secretion lasts much longer—up to 24 hours or more—due to the irreversible nature of the pump inhibition. The relationship between plasma concentration and effect is therefore not direct, and the area under the concentration-time curve (AUC) is a better predictor of antisecretory effect than peak plasma concentration (C_max) or half-life.

Dosing Considerations

The standard dosing regimen for most PPIs is once daily before breakfast. For conditions requiring more intensive acid suppression, such as severe erosive esophagitis or Zollinger-Ellison syndrome, twice-daily dosing may be employed. Intravenous formulations (e.g., pantoprazole, esomeprazole) are available for patients who cannot take oral medications; they bypass absorption issues and deliver the prodrug directly into the systemic circulation for uptake by parietal cells.

Therapeutic Uses/Clinical Applications

Proton pump inhibitors are indicated for a range of disorders mediated by gastric acid. Their profound and reliable acid suppression makes them first-line therapy for several conditions.

Approved Indications

• Gastroesophageal Reflux Disease (GERD): This is the most common indication. PPIs are used for healing erosive esophagitis, maintaining healing, and controlling symptoms in both erosive and non-erosive GERD. They are superior to H₂-receptor antagonists in healing rates and symptom resolution.
• Peptic Ulcer Disease: PPIs are central to the treatment of gastric and duodenal ulcers. They are used both for healing active ulcers and, in combination with antibiotics, for eradicating Helicobacter pylori (H. pylori). The elevated gastric pH created by PPIs enhances the stability and efficacy of antibiotics like clarithromycin and amoxicillin.
• Helicobacter pylori Eradication: All standard H. pylori eradication regimens include a PPI, typically combined with two or three antibiotics (e.g., clarithromycin and amoxicillin; or metronidazole, tetracycline, and bismuth).
• Stress Ulcer Prophylaxis: In critically ill patients at high risk for gastrointestinal bleeding (e.g., those on mechanical ventilation, with coagulopathy), intravenous PPIs are used to prevent stress-related mucosal damage.
• Nonsteroidal Anti-Inflammatory Drug (NSAID)-Induced Ulcer Prevention and Healing: PPIs are effective in preventing and treating ulcers and dyspepsia in patients requiring long-term NSAID therapy, including low-dose aspirin for cardioprotection.
• Zollinger-Ellison Syndrome: This rare gastrin-secreting tumor causes profound gastric acid hypersecretion. High-dose PPIs (often twice daily or more) are the treatment of choice for controlling acid output and symptoms.
• Functional Dyspepsia: A subset of patients with functional dyspepsia, particularly those with epigastric pain syndrome, may experience symptom relief with PPI therapy, though the response is less predictable than in GERD.

Off-Label Uses

Several off-label applications are supported by clinical evidence and are commonly encountered in practice.

• Extraesophageal Manifestations of GERD: PPIs are often empirically trialed in patients with chronic cough, laryngitis, asthma, or non-cardiac chest pain suspected to be related to reflux, though the evidence for efficacy is mixed and these conditions are less responsive than typical GERD.
• Eosinophilic Esophagitis: PPIs are used both diagnostically (as a PPI trial can improve symptoms and histology in some patients, defining a PPI-responsive esophageal eosinophilia) and therapeutically.
• Prevention of Rebleeding from Peptic Ulcers: Following endoscopic hemostasis of a bleeding ulcer, high-dose intravenous PPI therapy (e.g., bolus followed by continuous infusion) is used to stabilize the clot by maintaining an intragastric pH > 6, which promotes platelet aggregation and reduces clot dissolution.

Adverse Effects

Proton pump inhibitors are generally well-tolerated, especially with short-term use. However, long-term therapy, which is common, has been associated with a spectrum of potential adverse effects stemming from sustained hypochlorhydria. Many of these effects are related to the physiological roles of gastric acid beyond digestion.

Common Side Effects

These effects are typically mild and often resolve with continued therapy or dose adjustment.

• Gastrointestinal: Headache, diarrhea, nausea, abdominal pain, and flatulence are the most frequently reported. The diarrhea is often non-specific but may occasionally be related to alterations in gut microbiota.
• Central Nervous System: Dizziness and somnolence are infrequently reported.

Serious and Long-Term Adverse Reactions

With widespread long-term use, associations with several more significant conditions have been observed, though causality is not always firmly established and absolute risks for individuals are often low.

• Nutritional Deficiencies:
  • Vitamin B₁₂: Gastric acid is required to release protein-bound vitamin B₁₂ from food. Chronic acid suppression may impair B₁₂ absorption, potentially leading to deficiency, especially in elderly patients or those with marginal stores after years of therapy.
  • Magnesium: PPI-induced hypomagnesemia is a recognized adverse effect, potentially severe enough to cause tetany, seizures, and cardiac arrhythmias. The mechanism is not fully understood but may involve impaired passive absorption of magnesium in the small intestine. Magnesium levels typically normalize upon PPI discontinuation.
  • Iron and Calcium: Acid facilitates the reduction of dietary ferric iron (Fe³⁺) to the more absorbable ferrous form (Fe²⁺) and enhances calcium solubility. PPI use may modestly impair the absorption of non-heme iron and certain calcium salts (like calcium carbonate), though the clinical significance for bone health is debated in the context of adequate dietary intake.
• Increased Risk of Infections:
  • Community-Acquired Pneumonia: Gastric acid is a barrier to ingested pathogens. An increased risk of community-acquired pneumonia, particularly in the first few weeks of therapy, has been reported, possibly due to gastric colonization and subsequent microaspiration of bacteria.
  • Clostridioides difficile Infection: PPI use is associated with an increased risk of developing C. difficile-associated diarrhea, likely due to alterations in the gut microbiome that favor pathogen overgrowth.
  • Other Enteric Infections: Risk of other bacterial gastroenteritides (e.g., Salmonella, Campylobacter) may be elevated.
• Bone Health: Long-term, high-dose PPI use has been associated with a modest increase in the risk of hip, wrist, and spine fractures. The mechanism may involve impaired calcium absorption, though other factors likely contribute. The risk appears greatest in patients with other osteoporosis risk factors and those on prolonged therapy.
• Renal Disease: Observational studies suggest a potential link between long-term PPI use and an increased risk of chronic kidney disease and acute interstitial nephritis, a rare but serious hypersensitivity reaction that can lead to renal failure.
• Dementia and Cognitive Decline: Some epidemiological studies have reported an association between long-term PPI use and an increased risk of dementia, possibly mediated by increased β-amyloid levels due to impaired lysosomal degradation from altered vacuolar ATPase function or via vitamin B₁₂ deficiency. The evidence is inconsistent, and a causal relationship remains unproven.
• Cardiovascular Risk: Early concerns about a potential interaction between PPIs and clopidogrel centered on the inhibition of CYP2C19 by some PPIs (notably omeprazole), which could theoretically reduce the activation of clopidogrel, a prodrug. Current guidelines suggest using a PPI with less CYP2C19 inhibition (e.g., pantoprazole) if concomitant therapy is necessary in patients at high risk for gastrointestinal bleeding.

No proton pump inhibitor currently carries a black box warning from regulatory agencies like the U.S. Food and Drug Administration (FDA). However, the agency has issued safety communications regarding risks of fractures, C. difficile diarrhea, low magnesium, and acute interstitial nephritis.

Drug Interactions

Drug interactions with proton pump inhibitors arise from two primary mechanisms: inhibition of the cytochrome P450 enzyme system and elevation of gastric pH, which can alter the absorption of other drugs.

Major Drug-Drug Interactions

Interactions via CYP450 Inhibition

Some PPIs can inhibit specific CYP isoenzymes, potentially increasing the plasma concentrations of drugs metabolized by those pathways. The inhibitory potential varies among PPIs.

• Omeprazole and Esomeprazole: These are moderate inhibitors of CYP2C19. They can significantly increase the levels of drugs that are primarily metabolized by this enzyme, such as:
  • Clopidogrel: As mentioned, this is a clinically significant interaction. Clopidogrel requires activation by CYP2C19. Concomitant use of a strong CYP2C19 inhibitor like omeprazole may reduce the formation of the active metabolite, potentially diminishing its antiplatelet effect and increasing cardiovascular risk. Pantoprazole or rabeprazole are preferred if PPI co-therapy is essential.
  • Diazepam: Increased sedation and prolonged effect may occur.
  • Phenytoin: Risk of phenytoin toxicity (ataxia, nystagmus, drowsiness) is increased.
• Lansoprazole: Also a moderate CYP2C19 inhibitor, with a similar but not identical interaction profile to omeprazole.
• Pantoprazole and Rabeprazole: These agents have minimal inhibitory effects on CYP enzymes and are therefore less likely to participate in such metabolic interactions.

Interactions via pH-Dependent Absorption

Elevation of intragastric pH can alter the dissolution, stability, or ionization of co-administered drugs, affecting their bioavailability.

• Decreased Absorption: Drugs that require an acidic environment for optimal absorption may have their bioavailability reduced.
  • Ketoconazole, Itraconazole, Posaconazole (suspension): These weak-base antifungals require gastric acid for dissolution and absorption. PPI co-administration can lead to therapeutic failure. The tablet formulation of posaconazole and the newer drug isavuconazonium are less affected.
  • Atazanavir, Rilpivirine (HIV protease/non-nucleoside reverse transcriptase inhibitors): These drugs require an acidic pH for absorption. Concurrent PPI use is contraindicated or requires careful dose separation and monitoring.
  • Iron Salts (ferrous sulfate): Absorption of non-heme iron may be reduced, as previously discussed.
  • Mycophenolate Mofetil: The enteric-coated formulation’s absorption may be delayed and reduced, potentially lowering its immunosuppressive efficacy.
• Increased Absorption: Drugs that are acid-labile or whose absorption is enhanced in a less acidic environment may see increased bioavailability.
  • Digoxin: Elevated gastric pH may increase the dissolution and absorption of digoxin tablets, potentially leading to toxicity.

Contraindications

Absolute contraindications to PPI use are few but include:

• Known hypersensitivity to the drug or any component of the formulation.
• Concomitant use with rilpivirine-containing regimens due to the high risk of virologic failure and resistance from impaired absorption.
• Concomitant use with atazanavir without careful management, as per HIV treatment guidelines.

Use is also contraindicated in situations where gastric acid suppression could mask symptoms of underlying malignancy, such as in patients with alarm features (e.g., unintentional weight loss, anemia, dysphagia, hematemesis) without appropriate investigation.

Special Considerations

Use in Pregnancy and Lactation

PPIs are classified as FDA Pregnancy Category B (esomeprazole is Category C) in older classification systems, indicating no evidence of risk in animal studies, but adequate and well-controlled studies in pregnant women are lacking. Observational data in humans have not demonstrated a consistent pattern of major teratogenic risk. However, due to the inherent limitations of such data, PPIs should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. For GERD in pregnancy, lifestyle modifications and antacids or sucralfate are considered first-line, with H₂-receptor antagonists as second-line. PPIs may be reserved for severe, refractory cases. All PPIs are excreted in breast milk in low concentrations. While considered likely compatible with breastfeeding, the long-term effects on a nursing infant are unknown, and the lowest effective dose should be used.

Pediatric Considerations

PPIs are used in pediatric populations for conditions similar to those in adults, such as GERD and erosive esophagitis. Dosing is typically weight-based (mg/kg). Formulations may need adjustment; for example, capsules can be opened and the enteric-coated granules mixed with soft food for children unable to swallow pills. Liquid formulations are available for some agents. Long-term safety data in children are more limited than in adults, and the principle of using the lowest effective dose for the shortest necessary duration is paramount.

Geriatric Considerations

Elderly patients are frequent users of PPIs, often for extended periods. This population is particularly susceptible to the potential adverse effects of long-term therapy. They are at higher risk for C. difficile infection, community-acquired pneumonia, fractures (due to higher baseline osteoporosis risk), and drug-drug interactions (due to polypharmacy). Vitamin B₁₂ deficiency may be more clinically significant. Regular review of the ongoing indication for PPI therapy and attempts to deprescribe or step down to H₂-receptor antagonists are strongly recommended in geriatric practice.

Renal and Hepatic Impairment

Renal Impairment: Since PPIs are extensively metabolized and their inactive metabolites are renally excreted, dosage adjustment is generally not required in patients with renal impairment. However, caution is advised due to the potential association with acute interstitial nephritis and chronic kidney disease. Patients with end-stage renal disease should be monitored.

Hepatic Impairment: PPIs are metabolized in the liver. In patients with severe hepatic impairment (Child-Pugh Class C), the bioavailability of some PPIs may be increased due to reduced first-pass metabolism, and the elimination half-life may be prolonged. A dose reduction may be considered for some agents (e.g., omeprazole, esomeprazole). Pantoprazole, which has a dual route of elimination, may require less adjustment. Clinical monitoring for efficacy and adverse effects is prudent.

Summary/Key Points

• Proton pump inhibitors are prodrugs that irreversibly inhibit the H⁺/K⁺ ATPase (proton pump) on the secretory surface of gastric parietal cells, providing profound and sustained suppression of gastric acid secretion.
• Optimal oral dosing requires administration 30-60 minutes before a meal to coincide with activation of proton pumps, maximizing drug efficacy.
• Major clinical indications include healing and maintenance therapy for GERD and peptic ulcers, H. pylori eradication, prevention of NSAID-induced ulcers, and management of hypersecretory conditions like Zollinger-Ellison syndrome.
• While generally safe for short-term use, long-term PPI therapy is associated with potential risks, including increased susceptibility to certain infections (C. difficile, pneumonia), nutrient deficiencies (B₁₂, magnesium), bone fractures, and renal impairment.
• Significant drug interactions occur via two mechanisms: inhibition of CYP2C19 (most notably with omeprazole, affecting clopidogrel activation) and elevation of gastric pH (reducing absorption of drugs like ketoconazole and atazanavir).
• Inter-individual variability in response is influenced by CYP2C19 genetic polymorphism, which significantly affects the metabolism of omeprazole, lansoprazole, and esomeprazole.
• Clinical practice should emphasize using the lowest effective dose for the shortest duration necessary, with periodic re-evaluation of the ongoing need for therapy, especially in elderly patients.

Clinical Pearls

• For a patient starting clopidogrel who requires a PPI for GI protection, pantoprazole or rabeprazole may be preferred over omeprazole or esomeprazole due to their lower potential for CYP2C19 interaction.
• The development of acute diarrhea in a hospitalized patient on PPIs should prompt consideration of Clostridioides difficile infection.
• Unexplained hypomagnesemia, especially if recurrent, should trigger a review of the patient’s medication list for PPI use.
• In patients with suspected extraesophageal reflux symptoms (e.g., chronic cough, hoarseness), a time-limited (e.g., 8-week) empiric trial of a PPI is reasonable, but lack of response should lead to discontinuation and further diagnostic evaluation rather than indefinite therapy.
• When attempting to discontinue long-term PPI therapy, a gradual taper (e.g., halving the dose or switching to an H₂-receptor antagonist) may mitigate rebound acid hypersecretion and facilitate successful cessation.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.